Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: Off-the-shelf cellular therapies for cancer treatment
Company stage: Clinical
Diseases: T-cell acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), head and neck cancer, melanoma
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: San Diego, CA, USA and St. Louis, MO, USA
Wugen is a privately held biotech company. The company focuses on developing CAR-T and natural killer (NK) cells to kill malignant T cells and solid tumours. Wugen uses CRISPR for the deletion of the T-cell receptor (TCR), which enables the use of T cells from healthy donors without the risk of graft-versus-host disease.